458 related articles for article (PubMed ID: 28578693)
21. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Said TK; Medina D
Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
[TBL] [Abstract][Full Text] [Related]
22. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
[TBL] [Abstract][Full Text] [Related]
23. Baicalein induces G1 arrest in oral cancer cells by enhancing the degradation of cyclin D1 and activating AhR to decrease Rb phosphorylation.
Cheng YH; Li LA; Lin P; Cheng LC; Hung CH; Chang NW; Lin C
Toxicol Appl Pharmacol; 2012 Sep; 263(3):360-7. PubMed ID: 22820424
[TBL] [Abstract][Full Text] [Related]
24. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
[TBL] [Abstract][Full Text] [Related]
25. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
Zhao M; Scott S; Evans KW; Yuca E; Saridogan T; Zheng X; Wang H; Korkut A; Cruz Pico CX; Demirhan M; Kirby B; Kopetz S; Diala I; Lalani AS; Piha-Paul S; Meric-Bernstam F
Clin Cancer Res; 2021 Mar; 27(6):1681-1694. PubMed ID: 33414137
[TBL] [Abstract][Full Text] [Related]
26. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Finn RS; Dering J; Conklin D; Kalous O; Cohen DJ; Desai AJ; Ginther C; Atefi M; Chen I; Fowst C; Los G; Slamon DJ
Breast Cancer Res; 2009; 11(5):R77. PubMed ID: 19874578
[TBL] [Abstract][Full Text] [Related]
27. Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma.
Su D; Zhang D; Jin J; Ying L; Han M; Chen K; Li B; Wu J; Xie Z; Zhang F; Lin Y; Cheng G; Li JY; Huang M; Wang J; Wang K; Zhang J; Li F; Xiong L; Futreal A; Mao W
Nat Commun; 2019 Nov; 10(1):5076. PubMed ID: 31700061
[TBL] [Abstract][Full Text] [Related]
28. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
29. Curcumin potentiates the antitumor effects of 5-FU in treatment of esophageal squamous carcinoma cells through downregulating the activation of NF-κB signaling pathway in vitro and in vivo.
Tian F; Fan T; Zhang Y; Jiang Y; Zhang X
Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):847-55. PubMed ID: 23017833
[TBL] [Abstract][Full Text] [Related]
30. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
Baughn LB; Di Liberto M; Wu K; Toogood PL; Louie T; Gottschalk R; Niesvizky R; Cho H; Ely S; Moore MA; Chen-Kiang S
Cancer Res; 2006 Aug; 66(15):7661-7. PubMed ID: 16885367
[TBL] [Abstract][Full Text] [Related]
31. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
32. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
33. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
van Caloen G; Schmitz S; El Baroudi M; Caignet X; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
Mol Cancer Ther; 2020 Mar; 19(3):777-789. PubMed ID: 31924739
[TBL] [Abstract][Full Text] [Related]
34. Purpurogallin is a novel mitogen-activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo.
Xie X; Zu X; Liu F; Wang T; Wang X; Chen H; Liu K; Wang P; Liu F; Zheng Y; Bode AM; Dong Z; Kim DJ
Mol Carcinog; 2019 Jul; 58(7):1248-1259. PubMed ID: 31100197
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of proliferation and induction of G1-phase cell-cycle arrest by dFMGEN, a novel genistein derivative, in lung carcinoma A549 cells.
Peng B; Cao J; Yi S; Wang C; Zheng G; He Z
Drug Chem Toxicol; 2013 Apr; 36(2):196-204. PubMed ID: 22931124
[TBL] [Abstract][Full Text] [Related]
36. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
[TBL] [Abstract][Full Text] [Related]
37. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
Bronner SM; Merrick KA; Murray J; Salphati L; Moffat JG; Pang J; Sneeringer CJ; Dompe N; Cyr P; Purkey H; Boenig GL; Li J; Kolesnikov A; Larouche-Gauthier R; Lai KW; Shen X; Aubert-Nicol S; Chen YC; Cheong J; Crawford JJ; Hafner M; Haghshenas P; Jakalian A; Leclerc JP; Lim NK; O'Brien T; Plise EG; Shalan H; Sturino C; Wai J; Xiao Y; Yin J; Zhao L; Gould S; Olivero A; Heffron TP
Bioorg Med Chem Lett; 2019 Aug; 29(16):2294-2301. PubMed ID: 31307887
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo.
Liu X; Song M; Wang P; Zhao R; Chen H; Zhang M; Shi Y; Liu K; Liu F; Yang R; Li E; Bode AM; Dong Z; Lee MH
Int J Cancer; 2019 Aug; 145(4):1007-1019. PubMed ID: 30887517
[TBL] [Abstract][Full Text] [Related]
39. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
Fry DW; Harvey PJ; Keller PR; Elliott WL; Meade M; Trachet E; Albassam M; Zheng X; Leopold WR; Pryer NK; Toogood PL
Mol Cancer Ther; 2004 Nov; 3(11):1427-38. PubMed ID: 15542782
[TBL] [Abstract][Full Text] [Related]
40. Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8.
Qiu F; Liu L; Lin Y; Yang Z; Qiu F
Anticancer Agents Med Chem; 2019; 19(8):1021-1028. PubMed ID: 30848215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]